trans-beta-Asarone is an asarone isomer associated with calamus-type oils and is best treated as a restricted-risk phenylpropanoid rather than a wellness-forward aromatic. In the AromaForge archive it appears as a secondary but still significant constituent in the calamus-root record. The public literature contains both preclinical pharmacology and much stronger toxicology concern, including genotoxicity and carcinogenicity discussions for beta-asarone isomers. The evidence base therefore supports a conservative profile centered on identity, occurrence, and hazard context, not benefit-oriented copy.
Chemical identity and composition
The archive label uses trans-beta-asarone, but the easily accessible NIST entry for beta-asarone resolves the listed structure and stereochemical metadata to the Z-isomer naming set. Public calamus literature often discusses alpha- and beta-asarone nomenclature inconsistently across cis/trans or E/Z labels, so this record should be read as archive-specific naming for the calamus constituent identified in the linked oil COA.
Aroma and practical use
- Use the recorded spicy, sweet, woody, calamus-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A PubMed-indexed toxicology review reported that asarone isomers have been associated with cardiotoxicity, hepatotoxicity, reproductive toxicity, mutagenicity, and carcinogenicity.
This review provides the clearest high-level safety context and argues against casual use framing for beta-asarone-rich materials.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A PubMed-indexed metabolism paper described beta-asarone as genotoxic and carcinogenic in rodents and investigated its hepatic metabolism as part of the toxicology explanation.
This supports the hazard mechanism section more strongly than any isolated efficacy claim.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A full-text hepatotoxicity paper reported that due to potential toxic effects of beta-asarone, a temporary exposure limit of about 2 micrograms/kg body weight/day had been set for herbal products in that regulatory context.
This is practical evidence that public safety treatment of beta-asarone is restrictive rather than permissive.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot assessed
Not assessed in the available record.
Penetration enhancementNot assessed
Not assessed in the available record.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
recorded reference · IFRA Standard 110 (Amendment 40): cis- and trans-Asarone is a Prohibited fragrance substance (CAS 5273-86-9 among the covered isomers) - not permitted as a fragrance ingredientThe linked calamus-root oil record already applies a 0.01% IFRA-style asarone limit context, and the broader literature supports keeping this constituent in a restricted-risk category.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Public toxicology reviews repeatedly discuss genotoxicity and carcinogenicity concerns for beta-asarone isomers, so benefit-oriented constituent marketing would be misleading.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Asarone nomenclature across cis/trans and E/Z labels is inconsistent in the literature, so identity should be interpreted with care when comparing external sources to archive naming.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
metabolic_activation_to_genotoxic_intermediates
PubMed and PMC toxicology literature describe hepatic metabolism and downstream genotoxicity as central reasons for concern around beta-asarone exposure.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
reported_neuropharmacology_in_preclinical_models
Reviews summarize beta-asarone neuroprotective and signaling effects in animal and cell models, but these findings sit alongside significant toxicity concerns and do not justify medical claims.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (3)
- Literature naming for alpha/beta and cis/trans or E/Z asarone is inconsistent, which complicates exact isomer matching against archive labels.
- Most accessible positive pharmacology reports are preclinical and are outweighed here by the toxicology literature.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.